Welcome to our dedicated page for Vivani Medical SEC filings (Ticker: VANI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vivani Medical, Inc. (VANI) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including Current Reports on Form 8-K, Annual Reports on Form 10-K, and Quarterly Reports on Form 10-Q. Vivani is a Delaware-incorporated, Nasdaq-listed clinical-stage biopharmaceutical company developing NanoPortal™-based long-acting GLP-1 implants and, through its Cortigent subsidiary, neuromodulation devices for vision restoration and stroke recovery.
In its recent Form 8-K filings, Vivani has reported material events such as equity financings via private placements and a registered direct offering of common stock, including details on share purchase agreements, gross proceeds, and reliance on exemptions from registration under Regulation D. Other 8-Ks furnish press releases covering business updates, preliminary financial information, and clinical data from the LIBERATE-1 Phase 1 study of NPM-115 and preclinical results for NPM-139. The company also uses 8-Ks to describe its plans and key dates related to the proposed spin-off of Cortigent, Inc.
Vivani’s periodic reports, referenced in its news releases, include its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, which the company cites for more detailed risk factors and financial information. These filings discuss topics such as operating losses, research and development expenses, cash position, and the risks associated with developing and commercializing its product candidates.
On Stock Titan, users can review Vivani’s filings as they are made available from EDGAR and use AI-powered summaries to understand the significance of individual documents, from capital-raising agreements and clinical program updates to shareholder meeting results and Cortigent spin-off disclosures.
Vivani Medical, Inc. announced on September 4, 2025 that it has outlined clinical development plans for NPM-139, its investigational semaglutide implant intended for chronic weight management in patients who are obese or overweight with a related comorbidity. The disclosure is furnished as an exhibit (Press Release, Exhibit 99.1) to this Current Report and does not include financial metrics, timelines, enrollment targets, regulatory milestones, or expected costs. The filing is signed by Donald Dwyer, Chief Business Officer.
Vivani Medical reported a widening net loss of $13.4 million for the six months ended June 30, 2025 versus $11.4 million a year earlier, driven by higher R&D and general and administrative expenses. Cash and cash equivalents declined to $6.8 million at June 30, 2025 from $18.4 million at December 31, 2024, total assets fell to $28.9 million from $41.6 million, and stockholders' equity decreased to $4.9 million.
The company progressed its NanoPortal GLP-1 implant programs: the LIBERATE-1 first-in-human trial achieved full enrollment and the first implant administration with positive safety, tolerability and encouraging performance signals, prompting prioritization of NPM-139 (semaglutide implant) toward clinical development. Vivani also filed to spin off Cortigent and secured $21.25 million of committed equity purchase agreements beginning September 2025, and believes currently available cash will fund planned obligations for at least the next twelve months.
Vivani Medical entered a Share Purchase Agreement effective August 11, 2025 to sell 7,936,507 shares of common stock at $1.26 per share, the last reported sale price on that date. The placement is expected to generate approximately $10.0 million in gross proceeds to the Company, with issuances occurring over multiple closings through July 15, 2026, each subject to closing conditions.
The Company stated that no warrants or discounts were provided and that no placement agent or investment banking fees were incurred. The Shares will be issued in reliance on exemptions under Section 4(a)(2) and Rule 506 of Regulation D and have not been registered for resale. The filing attaches a Share Purchase Agreement and a press release and corporate slide presentation as exhibits.
Form 4 Filing Details: Aaron Mendelsohn, Director of Vivani Medical (VANI), received a non-qualified stock option grant on June 24, 2025, as part of the company's Non-Employee Director Compensation Policy.
Key Transaction Details:
- Granted 35,135 stock options to purchase common stock
- Exercise price set at $1.27 per share
- Options expire on June 23, 2035
- Vesting occurs on earlier of: first grant anniversary or next annual stockholder meeting
The filing was signed by Adam Mendelsohn as attorney-in-fact on June 26, 2025. This transaction represents standard annual director compensation and indicates continued board engagement. The vesting structure aligns with typical corporate governance practices for director equity compensation.
Vivani Medical (VANI) reported insider trading activity through a Form 4 filing for Director and 10% Owner Gregg Williams. The filing details two significant option-related transactions:
- On June 24, 2025, Williams was granted 35,135 non-qualified stock options with an exercise price of $1.27. These options vest fully on either the first anniversary or next annual stockholder meeting, whichever comes first.
- A correction was made to a previous January 1, 2025 option grant, adjusting the total beneficial ownership from 76,757 to 76,393 options (exercise price $1.16) due to a clerical error. These options vest quarterly.
The transactions reflect standard director compensation practices and demonstrate continued insider equity participation in the company. The filing was signed by Adam Mendelsohn as attorney-in-fact on June 26, 2025.
Vivani Medical Director Wilford Dean Baker received a non-qualified stock option grant on June 24, 2025, as part of the company's Non-Employee Director Compensation Policy. The grant details include:
- 35,135 options to purchase common stock
- Exercise price of $1.27 per share
- Expiration date of June 23, 2035
- Vesting occurs in full on either the first grant anniversary or next annual stockholder meeting, whichever comes first
The Form 4 filing, signed by Attorney-in-fact Adam Mendelsohn on June 26, 2025, represents a standard annual director compensation grant. The vesting is contingent on Baker's continued service through the vesting date. This equity compensation aligns the director's interests with those of shareholders through long-term stock ownership potential.
Director Daniel Bradbury reported two key transactions in Vivani Medical (VANI) stock options:
- Acquired 35,135 non-qualified stock options on June 24, 2025, with exercise price of $1.27. These options vest fully on either the first anniversary or next annual stockholder meeting, whichever comes first. This was part of the annual director compensation policy.
- Correction to previous grant from January 1, 2025: Total options adjusted down from 50,059 to 49,822 (reduction of 237) due to clerical error. These options have a $1.16 exercise price and vest quarterly.
The transactions reflect standard board compensation practices and administrative corrections rather than open market trading activity. All holdings are directly owned, with no indirect beneficial ownership reported.
Form 4 filing reveals that Alexandra L. Popoff, Director at Vivani Medical (VANI), received a non-qualified stock option grant on June 24, 2025. Key details of the transaction:
- Granted 35,135 stock options to purchase common stock
- Exercise price set at $1.27 per share
- Options expire on June 23, 2035
- Vesting occurs on earlier of: - First anniversary of grant date - Next annual stockholder meeting
This grant was made as part of the company's Non-Employee Director Compensation Policy. The vesting is subject to continued service through the vesting date. The filing was submitted through an attorney-in-fact on June 26, 2025.
Vivani Medical, Inc. (Nasdaq: VANI) filed a Form 8-K to disclose the voting results of its 24 June 2025 Annual Meeting of Stockholders. A quorum was achieved with 37.1 million of 59.2 million outstanding shares represented. All six director nominees—Gregg Williams, Aaron Mendelsohn, Dean Baker, Alexandra Popoff, Adam Mendelsohn and Daniel Bradbury—were elected, each receiving roughly 25 million votes in favor versus approximately 0.4-0.6 million withheld, and 11.8 million broker non-votes. Stockholders also (1) ratified BPM LLP as independent auditor for fiscal 2025 with 36.5 million votes in favor and minimal opposition, and (2) approved, on a non-binding basis, executive compensation with 23.1 million votes for, 0.6 million against, 1.7 million abstentions and 11.8 million broker non-votes. No other matters were presented.